EARNINGS & CATALYSTS · November 2, 2026
Pfizer earnings preview: can newer medicines and cost savings sustain its outlook on November 3?
Pfizer’s November 3 earnings will test growth beyond COVID products, cost savings and the full-year outlook. Compare its last two reports with recent Merck results and the latest completed charts.
| Company | Report date | Window | EPS estimate | Revenue estimate |
|---|---|---|---|---|
| Pfizer Inc. (PFE) | November 3, 2026Issuer confirmed | Before open | 0.73 | 15.85B |
1) When Pfizer reports and what expectations mean
Pfizer confirms that its third-quarter 2026 performance report will be issued on the morning of November 3. Release before open is expected; the announcement does not state an exact report-release time. The quarter is still unreleased. MarketBeat’s October 27 preview put revenue consensus near $15.86 billion. Estimates vary by provider and date. The figures in the earnings comparison image use each historical release’s identified consensus, with adjusted diluted profit per share compared on a matching basis. EPS means profit per share; adjusted EPS removes items specified by management.
2) How Pfizer makes money
Pfizer develops and sells prescription medicines and vaccines, with additional income from partnerships and royalties. Its portfolio spans cancer, cardiovascular disease, infectious disease and other areas. Growth depends on expanding treatment use and launching medicines before older products lose market protection.
3) The next operating test
The earnings decision is whether newer products and cost savings can support the outlook as COVID-related demand normalizes. Watch the product mix and cash generation, with a separate assessment of clinical-development progress. A successful trial or approval can expand an opportunity, while commercial uptake still takes time. In August, Pfizer raised the lower end of its annual sales range from $59.5 billion to $60.5 billion and kept the upper end at $62.5 billion. It maintained adjusted profit per share at $2.80–$3.00. A durable improvement would combine sales progress with cash generation, rather than depend only on accounting adjustments.
4) What the previous two quarters show
The June-quarter release reported $15.034 billion of revenue and $0.77 in adjusted diluted profit per share. Reported results showed a $0.04 loss per share, including $4.3 billion of non-cash intangible-asset impairments. Those charges help explain why adjusted and reported profit tell different stories. For the March quarter, revenue was $14.451 billion, reported profit per share was $0.47 and adjusted profit per share was $0.75. Pfizer maintained its outlook at that time. The image calculates surprises against MarketBeat’s historical release comparisons. Stock reactions run from the prior regular close to the release-day close, using the same stock-price basis. A past beat does not establish the next outcome.
5) Recent peer evidence
Merck reported on October 29: quarterly sales were $18.085 billion and non-GAAP profit per share was $2.49, above the provider’s $17.33 billion and $2.09 consensus. Its full-year non-GAAP outlook rose to $2.77–$2.82 from $2.66–$2.76 and includes substantial transaction charges. Merck is useful oncology and vaccine context, but its products and accounting adjustments differ from Pfizer’s. The Merck share-price comparison covers the October 28 close to the October 29 close. It is an observed reaction over that window, rather than proof that a single result caused the move.
6) Financial risks and chart levels
Patent expirations and government pricing rules can reduce revenue from established medicines. Clinical failures, launch costs and acquisition impairments can reduce returns on research spending. Cash must also support debt, investment and the dividend; a strong adjusted-profit figure alone does not settle that question. The financial image shows three years on a comparable product, alliance and royalty revenue basis. Earlier figures use a different presentation and are retained in the working evidence. The latest completed chart ends October 30, 2026 at $30.52. Recent trading supports approximate areas around $30.10–$30.45 and $29.20–$29.50. Holding the higher area would support the recovery; falling below the lower area would weaken it. Earnings gaps can cross these levels.
7) How the business makes money
Pfizer develops and sells prescription medicines and vaccines, with additional income from partnerships and royalties. Its portfolio spans cancer, cardiovascular disease, infectious disease and other areas. Growth depends on expanding treatment use and launching medicines before older products lose market protection.
8) What to watch
The earnings decision is whether newer products and cost savings can support the outlook as COVID-related demand normalizes. Watch the product mix and cash generation, with a separate assessment of clinical-development progress. A successful trial or approval can expand an opportunity, while commercial uptake still takes time.
9) Recently reported peers
Merck reported on October 29: quarterly sales were $18.085 billion and non-GAAP profit per share was $2.49, above the provider’s $17.33 billion and $2.09 consensus. Its full-year non-GAAP outlook rose to $2.77–$2.82 from $2.66–$2.76 and includes substantial transaction charges. Merck is useful oncology and vaccine context, but its products and accounting adjustments differ from Pfizer’s.
10) Risks into the report
Patent expirations and government pricing rules can reduce revenue from established medicines. Clinical failures, launch costs and acquisition impairments can reduce returns on research spending. Cash must also support debt, investment and the dividend; a strong adjusted-profit figure alone does not settle that question.